Revenue Distribution by Industries:

• Pharmaceutical Research and Development: 60%
• Biotechnology Services: 25%
• Licensing Fees and Partnerships: 15%

TOP 3 Markets and their Percentage Shares:

• China: 45%
• USA: 30%
• Europe: 15%

HitGen Inc. generates the majority of its revenue from pharmaceutical research and development, which is the company's core competency. Biotechnology services complement the portfolio and also contribute significantly to revenue.

Geographically, China is HitGen's largest market, driven by a strong presence and growing demand for biotechnological solutions domestically. The USA and Europe follow, with these markets benefiting from strategic partnerships and licensing agreements.

Production Sites: Chengdu, China

HitGen Inc. has its headquarters and production facilities in Chengdu, China. The company is known for its work in the field of DNA-encoded chemistry and the development of new drugs. Chengdu serves as a central hub for research, development, and production, enabling the company to operate efficiently and distribute its products globally.

Strategy for Future Growth:

HitGen Inc. pursues a multi-faceted growth strategy based on innovation, partnerships, and market expansion.

The company heavily invests in research and development of new drugs, particularly through the use of its DNA-encoded library technology. This technology enables HitGen to efficiently identify and develop new active substances.

In addition, HitGen relies on strategic partnerships with leading pharmaceutical companies worldwide to maximize the reach and effectiveness of its research efforts. These collaborations allow the company to deploy its technologies more broadly and benefit from the resources and networks of its partners.

Another focus is on geographical expansion, particularly in the markets of North America and Europe, to strengthen global presence and tap into new sources of revenue.

Imported Raw Materials: Chemical reagents, Biotechnological materials

Main Supplier Countries: USA, Germany, Japan

HitGen Inc. is a company specializing in the development of DNA-encoded libraries and biotechnological solutions. For their research and development activities, HitGen imports a variety of chemical reagents and biotechnological materials.

The USA is a significant supplier, especially for specialized chemical reagents used in drug discovery. Germany and Japan also supply high-quality biotechnological materials used in the development of DNA-encoded libraries and other biotechnological applications.

These imports are crucial for maintaining HitGen's high standards and innovation in biopharmaceutical research.

Market Share: Estimated at 10% in the field of DNA-linked chemistry (2026)
R&D Expenses: 25% of revenue (2025)
Patent Portfolio: Over 300 patents (2026)

HitGen Inc. has established itself as a leading company in the field of DNA-linked chemistry. The company's competitive advantage lies in its strong R&D orientation, supported by significant investments in research and development. This enables HitGen to bring innovative solutions and products to the market that are difficult for competitors to replicate.

The extensive patent portfolio of over 300 patents protects technological advancements and secures a strategic advantage for the company over its competitors. Additionally, HitGen benefits from strategic partnerships and alliances with major pharmaceutical companies, facilitating access to new markets and technologies.

Overall, HitGen positions itself as a company with a significant competitive advantage in the industry due to its innovation capabilities, strategic partnerships, and strong patent portfolio.

Institutional Investor Share: 45% (estimated, 2025)

Insider Buys/Sells: No significant transactions in the last year (2025)

The institutional investor share in HitGen Inc. is estimated to be around 45%. This indicates a strong interest from institutional investors in the company, reflecting confidence in its long-term strategy and growth potential.

In 2025, there were no significant insider transactions, which could suggest a stable assessment of the company's value by management. A lack of insider buys or sells may also indicate that executives are content with the current valuation of the company.

Market share of HitGen Inc.: Estimate 3-5% (2026)

Main competitors and their market shares:

1. WuXi AppTec: Estimate 15-18%
2. Pharmaron: Estimate 10-12%
3. Viva Biotech: Estimate 8-10%
4. ChemPartner: Estimate 5-7%
5. Asymchem: Estimate 4-6%

Moat of HitGen Inc.: HitGen Inc. is known for its leading position in the field of DNA-encoded molecule libraries, which represents a technological moat. This technology enables the company to efficiently discover and develop new drugs, providing a significant advantage compared to traditional methods.

Compared to competitors, WuXi AppTec has a broader moat due to its comprehensive service platform, ranging from drug discovery to production. Pharmaron and Viva Biotech also benefit from integrated services and a strong global presence, giving them a strategic advantage.

In summary, HitGen has a specific technological advantage, but some competitors may have a stronger moat due to their more comprehensive services and global reach.

Revenue Growth: 18% (2025) R&D Expenses: 25% of revenue (2025) Partnerships: Over 50 strategic alliances (2025)

HitGen Inc. achieved an impressive revenue growth of 18% in 2025, attributed to the increasing acceptance of its platform technologies and expansion into international markets. The high investment in research and development, accounting for 25% of revenue, underscores the company's commitment to innovation and the development of new products.

The company has formed over 50 strategic alliances with leading pharmaceutical and biotechnology companies, strengthening its market position and opening up future growth opportunities. These partnerships could lead to an increased pipeline of potential drug candidates, potentially enhancing the company's value in the long term.

Overall, HitGen Inc. demonstrates strong fundamental metrics and a clear strategic direction focusing on innovation and growth. This could make the stock an attractive investment, especially for investors interested in the long-term development in the biotechnology sector.

Dividend payment: No dividend (2026)

HitGen Inc. currently does not pay any dividends to its shareholders. The company has focused on research and development in recent years, particularly in the field of DNA-encoded chemistry platforms and drug discovery.

As HitGen operates in a highly research-intensive industry, it typically reinvests its profits into developing new technologies and partnerships. This is a common practice for companies in the biotechnology sector that are in a growth phase. Analysts expect the company to continue investing its resources in expansion and innovation rather than distributing dividends.